INTERNATIONAL PATENT: SIGNALCHEM LIFESCIENCES CORPORATION FILES APPLICATION FOR "A COMBINATION OF THE AXL INHIBITOR SLC-391 AND A PD-1 INHIBITOR FOR USE IN THE TREATMENT OF BLOOD CANCER"

GENEVA, Aug. 19 -- SIGNALCHEM LIFESCIENCES CORPORATION (110-13120 Vanier PlaceRichmond, British Columbia V6V 2J2) filed a patent application (PCT/US2025/014420) for "A COMBINATION OF THE AXL INHIBITOR SLC-391 AND A PD-1 INHIBITOR FOR USE IN THE TREATMENT OF BLOOD CANCER" on Feb 04, 2025. With publication no. WO/2025/170888, the details related to the patent application was published on Aug 14, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): AHN, Yehyeon (c/o SignalChem Lifesciences Corporation110-13120 Vanier PlaceRichmond, British Columbia V6V 2J2), CHEN, Min (c/o SignalChem Lifesciences Co...